Abstract | BACKGROUND: METHODS: RESULTS: The average BP was 126.3/74.7 and 129.5/76.6 mmHg, respectively (P < 0.001). Olmesartan delayed the time to onset of microalbuminuria by 25% (hazard ratio = 0.75; 95% confidence interval = 0.61-0.92, P = 0.007). Patients with a baseline SBP above the median of 136.7 mmHg and a SBP reduction above the median of 17.45 mmHg had a lower incidence of microalbuminuria than patients with a SBP reduction of less than 17.45 (8.1 vs. 11.2%, P < 0.0001). Independent from the baseline BP and the degree of BP reduction a 15-39% increase in the time to onset of microalbuminuria was detectable by olmesartan treatment. Cardiovascular events were comparable and occurred in 93 (4.6%) patients taking olmesartan and 86 (4.4%) taking placebo. CONCLUSION: Patients with a better BP reduction are less likely to develop microalbuminuria. Treatment with olmesartan delayed the onset of microalbuminuria independent of the baseline BP and the degree of BP reduction.
|
Authors | Jan Menne, Joseph L Izzo Jr, Sadayoshi Ito, Andrzej Januszewicz, Shigehiro Katayama, Christos Chatzykirkou, Albert Mimran, Ton J Rabelink, Eberhard Ritz, Luis M Ruilope, Lars C Rump, Giancarlo Viberti, Hermann Haller, ROADMAP investigators |
Journal | Journal of hypertension
(J Hypertens)
Vol. 30
Issue 4
Pg. 811-8; discussion 818
(Apr 2012)
ISSN: 1473-5598 [Electronic] England |
PMID | 22418908
(Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial)
|
Chemical References |
- Antihypertensive Agents
- Imidazoles
- Tetrazoles
- olmesartan
|
Topics |
- Albuminuria
(etiology, prevention & control)
- Antihypertensive Agents
(therapeutic use)
- Blood Pressure
(drug effects, physiology)
- Diabetes Mellitus, Type 2
(complications, drug therapy, urine)
- Double-Blind Method
- Drug Therapy, Combination
- Female
- Humans
- Hypertension
(complications, drug therapy, urine)
- Imidazoles
(therapeutic use)
- Male
- Middle Aged
- Tetrazoles
(therapeutic use)
- Treatment Outcome
|